Table 3.
PRDM5 methylation and expression and other molecular features of serrated and conventional polyp subgroups
| Serrated Polyps | Conventional Adenomas | P value | ||||
|---|---|---|---|---|---|---|
| MVHP | SSA | TSA | TVA | TA | Serrated vs conventional | |
| N | 19 | 20 | 20 | 20 | 20 | - |
| PRDM5 Methylation | 2 (11%) | 2 (10%) | 2 (10%) | 0 | 0 | 0.08 |
| PRDM5 Average | 3.4 | 2.2 | 3.6 | 1.1 | 0.4 | 0.01 |
| PMR score | ||||||
| PRDM5 IHC | 5 (26%) | 12 (60%) | 12 (60%) | 12 (60%) | 11 (55%) | 0.5 |
| Negative Expression | ||||||
| BRAF mutation | 18 (95%) | 17 (85%) | 13 (65%) | 0 | 0 | <0.0001 |
| KRAS mutation | 0 | 1 (5%) | 4 (20%) | 3 (15%) | 1 (5%) | 1.0 |
| CIMP High | 2 (11%) | 12 (60%) | 9 (45%) | 0 | 0 | <0.0001 |
| Nuclear Beta-Catenin | 0 | 0 | 3 (15%) | 17 (85%) | 9 (45%) | <0.0001 |
Significant p values indicated in bold text.